TuHURA CEO to Discuss Immuno-Oncology Pipeline at H.C. Wainwright Conference
Event summary
- TuHURA Biosciences CEO James A. Bianco to participate in fireside chat at H.C. Wainwright BioConnect Investor Conference on May 19, 2026.
- Company's lead innate immune agonist IFx-2.0 in Phase 3 trial for Merkel Cell Carcinoma.
- TBS-2025 VISTA inhibitor advancing to Phase 1b/2 in mutNPM1 r/r AML.
- Delta Opioid Receptor technology being leveraged for first-in-class ADCs targeting Myeloid Derived Suppressor Cells.
The big picture
TuHURA's participation in the H.C. Wainwright conference comes as the company advances multiple immuno-oncology candidates aimed at overcoming resistance to existing therapies. The strategic focus on both primary and acquired resistance positions TuHURA in a competitive segment of the oncology market, where checkpoint inhibitor resistance remains a significant unmet need. The company's pipeline diversification, including ADCs and VISTA inhibitors, could enhance its valuation if clinical milestones are met.
What we're watching
- Clinical Progress
- Whether IFx-2.0 can demonstrate efficacy in overcoming primary resistance to checkpoint inhibitors in the Phase 3 trial.
- Pipeline Expansion
- The pace at which TBS-2025 advances through Phase 1b/2 and the potential for additional indications.
- Technology Differentiation
- How TuHURA's Delta Opioid Receptor technology will position it against competitors in targeting Myeloid Derived Suppressor Cells.
Related topics